Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection

Virology Journal

Volumn 4, Issue , 2007, Pages

  Raaben, Matthijs ^a   Einerhand, Alexandra W C ^b   Taminiau, Lucas J A ^b   Van Houdt, Michel ^b   Bouma, Janneke ^b   Raatgeep, Rolien H ^b   Büller, Hans A ^b   De Haan, Cornelis A M ^a   Rossen, John W A ^b,c,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d CPRLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; VIRUS PROTEIN; VIRUS RNA; ISOENZYME;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; CORONAVIRUS; ENZYME ACTIVITY; HEPATITIS VIRUS; HUMAN; HUMAN CELL; PROGENY; PROTEIN SYNTHESIS; RNA INTERFERENCE; VIRUS REPLICATION; BIOSYNTHESIS; CELL STRAIN CACO 2; GENETICS; GROWTH, DEVELOPMENT AND AGING; MURINE HEPATITIS CORONAVIRUS; PHYSIOLOGY;

MURINE HEPATITIS VIRUS;

CACO-2 CELLS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MURINE HEPATITIS VIRUS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA INTERFERENCE; RNA, VIRAL; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 34250617906     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-55     Document Type: Article

References (37)

1. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. AG Spencer JW Woods T Arakawa Singer WL Smith, J Biol Chem 1998 273 16 9886 9893 10.1074/jbc.273.16.9886 9545330
2. Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. R Newton LM Kuitert M Bergmann IM Adcock PJ Barnes, Biochem Biophys Res Commun 1997 237 1 28 32 10.1006/bbrc.1997.7064 9266823
3. Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF-kappaB and JNK activation. R Newton DA Stevens LA Hart M Lindsay IM Adcock PJ Barnes, FEBS Lett 1997 418 1-2 135 138 10.1016/S0014-5793(97)01362-8 9414112
4. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. M Betz BS Fox, J Immunol 1991 146 1 108 113 1845802
5. Analysis of the defects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. II. Role of monocytes and the increased sensitivity of rheumatoid arthritis lymphocytes to prostaglandin E. F Hasler HG Bluestein NJ Zvaifler LB Epstein, J Immunol 1983 131 2 768 772 6306107
6. The role and regulation of COX-2 during viral infection. SA Steer JA Corbett, Viral Immunol 2003 16 4 447 460 10.1089/088282403771926283 14733733
7. The effect of prostaglandins on the multiplication and cell-to-cell spread of herpes simplex virus type 2 in vitro. DA Baker J Thomas J Epstein D Possilico ML Stone, Am J Obstet Gynecol 1982 144 3 346 349 6289665
8. Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 6. Role for cyclic AMP-responsive element-binding protein and activator protein-1. ME Janelle A Gravel J Gosselin MJ Tremblay L Flamand, J Biol Chem 2002 277 34 30665 30674 10.1074/jbc.M203041200 12068008
9. COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. TL Symensma D Martinez-Guzman Q Jia E Bortz TT Wu N Rudra-Ganguly S Cole H Herschman R Sun, J Virol 2003 77 23 12753 12763 14610197 10.1128/JVI.77.23.12753-12763.2003
10. Effect of prostaglandins PGE2 and PGF alpha 2 on the mean plaque size of bovine herpesvirus 1. E Thiry B Mignon F Thalasso PP Pastoret, Ann Rech Vet 1988 19 4 291 293 2852912
11. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. H Zhu JP Cong D Yu WA Bresnahan TE Shenk, Proc Natl Acad Sci U S A 2002 99 6 3932 3937 11867761 10.1073/pnas.052713799
12. Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. N Ray ME Bisher LW Enquist, J Virol 2004 78 23 12964 12974 15542648 10.1128/JVI.78.23.12964-12974.2004
13. Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. D Rott J Zhu MS Burnett YF Zhou A Zalles-Ganley J Ogunmakinwa SE Epstein, J Am Coll Cardiol 2003 41 10 1812 1819 10.1016/S0735-1097(03)00304-8 12767669
14. Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. D Pyeon FJ Diaz GA Splitter, J Virol 2000 74 12 5740 5745 10823885 10.1128/JVI.74.12.5740-5745.2000
15. Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. JW Rossen J Bouma RH Raatgeep HA Buller AW Einerhand, J Virol 2004 78 18 9721 9730 15331705 10.1128/JVI.78.18.9721-9730.2004
16. Synergistic activation of the human cytomegalovirus major immediate early promoter by prostaglandin E2 and cytokines. JN Kline GM Hunninghake B He MM Monick GW Hunninghake, Exp Lung Res 1998 24 1 3 14 9457465
17. Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: implications for viral transmission. M Moriuchi H Inoue H Moriuchi, J Virol 2001 75 1 192 198 11119588 10.1128/JVI.75.1.192-198.2001
18. Prostaglandin E2 Up-regulates HIV-1 long terminal repeat-driven gene activity in T cells via NF-kappaB-dependent and -independent signaling pathways. N Dumais B Barbeau M Olivier MJ Tremblay, J Biol Chem 1998 273 42 27306 27314 10.1074/jbc.273.42.27306 9765256
19. Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. MM Hayes BR Lane SR King DM Markovitz MJ Coffey, Cell Immunol 2002 215 1 61 71 10.1016/S0008-8749(02)00017-5 12142037
20. The effect of prostaglandins on the replication of adenovirus wild types and temperature-sensitive mutants. J Ongradi A Telekes J Farkas I Nasz M Bendinelli, Acta Microbiol Immunol Hung 1994 41 2 173 188 7804721
21. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. SR Weiss S Navas-Martin, Microbiol Mol Biol Rev 2005 69 4 635 664 16339739 10.1128/MMBR.69.4.635-664.2005
22. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. C Drosten S Gunther W Preiser S van der Werf HR Brodt S Becker H Rabenau M Panning L Kolesnikova RA Fouchier A Berger AM Burguiere J Cinatl M Eickmann N Escriou K Grywna S Kramme JC Manuguerra S Muller V Rickerts M Sturmer S Vieth HD Klenk AD Osterhaus H Schmitz HW Doerr, N Engl J Med 2003 348 20 1967 1976 10.1056/NEJMoa030747 12690091
23. Identification of a new human coronavirus. L van der Hoek K Pyrc MF Jebbink W Vermeulen-Oost RJ Berkhout KC Wolthers PM Wertheim-van Dillen J Kaandorp J Spaargaren B Berkhout, Nat Med 2004 10 4 368 373 10.1038/nm1024 15034574
24. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. PC Woo SK Lau CM Chu KH Chan HW Tsoi Y Huang BH Wong RW Poon JJ Cai WK Luk LL Poon SS Wong Y Guan JS Peiris KY Yuen, J Virol 2005 79 2 884 895 15613317 10.1128/JVI.79.2.884-895.2005
25. Pattern of disease after murine hepatitis virus strain 3 infection correlates with macrophage activation and not viral replication. M Pope O Rotstein E Cole S Sinclair R Parr B Cruz R Fingerote S Chung R Gorczynski L Fung, J Virol 1995 69 9 5252 5260 7636967
26. Prostaglandin E2 (PGE2) alters the pathogenesis of MHV-3 infection in susceptible BALB/cJ mice. M Abecassis J Falk V Dindzans W Lopatin L Makowka G Levy R Falk, Adv Exp Med Biol 1987 218 465 466 2829560
27. Amino acids 1 to 422 of the spike protein of SARS associated coronavirus are required for induction of cyclooxygenase-2. M Liu C Gu J Wu Y Zhu, Virus Genes 2006 33 3 309 317 10.1007/s11262-005-0070-4 16991002
28. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. X Yan Q Hao Y Mu KA Timani L Ye Y Zhu J Wu, Int J Biochem Cell Biol 2006 38 8 1417 1428 10.1016/j.biocel. 2006.02.003 16546436
29. Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways. M Liu Y Yang C Gu Y Yue KK Wu J Wu Y Zhu, Faseb J 2007
30. Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome. CH Lee RF Chen JW Liu WT Yeh JC Chang PM Liu HL Eng MC Lin KD Yang, J Immunol 2004 172 12 7841 7847 15187168
31. Mouse hepatitis virus strain A59 is released from opposite sides of different epithelial cell types. JW Rossen GJ Strous MC Horzinek PJ Rottier, J Gen Virol 1997 78 ( Pt 1) 61 69 9010286
32. Viral protein synthesis in mouse hepatitis virus strain A59-infected cells: effect of tunicamycin. PJ Rottier MC Horzinek BA van der Zeijst, J Virol 1981 40 2 350 357 6275093
33. Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. CA de Haan Z Li E te Lintelo BJ Bosch BJ Haijema PJ Rottier, J Virol 2005 79 22 14451 14456 16254381 10.1128/JVI.79.22.14451-14456.2005
34. Coronaviruses as vectors: position dependence of foreign gene expression. CA de Haan L van Genne JN Stoop H Volders PJ Rottier, J Virol 2003 77 21 11312 11323 14557617 10.1128/JVI.77.21.11312-11323.2003
35. Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly. H Vennema L Heijnen A Zijderveld MC Horzinek WJ Spaan, J Virol 1990 64 1 339 346 2403441
36. Indomethacin has a potent antiviral activity against SARS coronavirus. C Amici A Di Coro A Ciucci L Chiappa C Castilletti V Martella N Decaro C Buonavoglia MR Capobianchi MG Santoro, Antivir Ther 2006 11 8 1021 1030 17302372
37. Redirecting coronavirus to a nonnative receptor through a virus-encoded targeting adapter. MH Verheije T Wurdinger VW van Beusechem CA de Haan WR Gerritsen PJ Rottier, J Virol 2006 80 3 1250 1260 16415002 10.1128/JVI.80.3. 1250-1260.2006